Amerise Biosciences Ltd

Snehjeev Ventures Pvt Ltd, along with its persons acting in concert (PACs), has acquired 5,962,355 equity shares in Amerise Biosciences Ltd. This acquisition represents a 9.02% holding in the target company. The shares were acquired through open market transactions. The total equity share capital of Amerise Biosciences before and after the acquisition remains Rs. 6,60,69,000/-, comprising 66,06,900 equity shares of Rs. 10/- each. This disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Snehjeev Ventures Pvt Ltd, along with Persons Acting in Concert (PACs), has disclosed a reduction in their shareholding in Amerise Biosciences Ltd. The acquisition/sale, conducted via open market, resulted in their stake decreasing from 9.31% to 8.83%. The transaction involved the sale of 318,285 shares, bringing the total holding of Snehjeev Ventures and its PACs to 5,835,161 shares. The total equity share capital of Amerise Biosciences is Rs. 6,60,69,000/-.

Snehjeev Ventures Pvt Ltd and its Persons Acting in Concert (PACs) have disclosed the sale of 318,285 equity shares in Amerise Biosciences Ltd. This transaction, executed via the open market on July 15, 2026, resulted in their total shareholding falling below the 9% threshold. Prior to the sale, Snehjeev Ventures and PACs held 6,153,446 shares, representing 9.31% of the total capital. After the sale, their holding reduced to 5,835,161 shares, constituting 8.83% of the company's equity. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Snehjeev Ventures Pvt Ltd, along with persons acting in concert (PACs), has acquired an additional 38,574 equity shares, representing 0.06% of the total capital of Amerise Biosciences Ltd. This acquisition brings their total holding to 5,972,466 equity shares, which constitutes 9.04% of the company's total capital. The acquisition was made through the open market. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, as of July 6, 2026. The total equity share capital of Amerise Biosciences Ltd. remains unchanged at Rs. 6,60,69,000/-.

Amerise Biosciences Ltd has announced the closure of its trading window for dealing in the company's securities. This closure will be effective from Wednesday, July 1, 2026, and will continue until 48 hours after the declaration of the unaudited financial results for the first quarter ended June 30, 2026. The specific date for the board meeting to approve these results will be communicated later. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Snehjeev Ventures Pvt Ltd, along with persons acting in concert (PACs) Rushank SS Lunkad, Sneha Lunkad, and Riddhi Lunkad, has acquired 4,650,896 equity shares in Amerise Biosciences Ltd. This acquisition represents 7.04% of the total share capital. The shares were acquired through the open market. Prior to this transaction, the acquirer group held 6.99% of the company's shares. The total equity share capital of Amerise Biosciences before and after the acquisition remains Rs. 6,60,69,000.

Amerise Biosciences Ltd's board approved the audited financial results for the year ended March 31, 2026. The company reported total income of ₹25.52 lakhs and a net profit after tax of ₹1.61 lakhs for the year ended March 31, 2026. The auditor's report has an unmodified opinion. The board meeting concluded on May 5, 2026.

Amerise Biosciences Ltd's board approved the audited financial results for the year ended March 31, 2026. The auditor's report has an "Unmodified Opinion". The company reported total income of ₹25.52 Lakhs and a net profit after tax of ₹1.61 Lakhs for the year ended March 31, 2026. The board meeting commenced at 04:45 PM and concluded at 05:15 PM on May 5, 2026.

Snehjeev Ventures Pvt Ltd, along with Persons Acting in Concert (PACs), increased their shareholding in Amerise Biosciences Ltd to 5.34% through open market acquisition. The acquisition, which crossed the 5% holding threshold on April 24, 2026, involved the acquisition of 560,000 shares, representing 0.85% of the total share capital. Before this acquisition, the acquirer along with PACs held 4.49% of the company.

Snehjeev Ventures Pvt Ltd, along with Persons Acting in Concert (PACs) Sneha Lunkad, Rushank SS Lunkad, and Riddhi Lunkad, has disclosed the acquisition of 560,000 equity shares of Amerise Biosciences Ltd through open market purchases. This acquisition, completed on April 24, 2026, represents 0.85% of Amerise Biosciences' total capital. Following this transaction, the combined holding of Snehjeev Ventures and its PACs in Amerise Biosciences has increased from 4.49% (2,969,664 shares) to 5.34% (3,529,664 shares), crossing the 5% threshold, as per Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.